Update Series (2022) Lesson 21: The Changing Role of Fluoroquinolones for Prophylaxis and Treatment of Urological Infections

Audio Lessons - Listen on-the-go for Free!

Did you know you can stream Update Series lessons from your favorite Podcast app (including Apple Podcast and Pocket Casts)?
Add the Update Series Audio Lessons to Your Podcast Library Today!

Please follow the download instructions to your preferred Podcast app, located below. 

Apple Podcasts 
1. Copy your Personal Subscriber Feed URL*: https://university.auanet.org/updateseries/rssaudio.cfm?userID=
2. Open Apple Podcasts app.
3. Click on "Library" on the bottom row of icons. 
4. Click "…" on the top right corner, and select "Add a Show by URL". 
5. Paste your copied personal URL and tap "Follow". 

Pocket Casts
1. Copy your Personal Subscriber Feed URL*: https://university.auanet.org/updateseries/rssaudio.cfm?userID=
2. Open Pocket Casts app.
3. On the “Discover” tab, paste your copied personal feed URL in the Search field and hit “Search”. 
4. Click on the Update Series Podcast in search results.
5. Click "Subscribe". 

*Please note that this URL is individual to you and only available to Update Series 2022 subscribers. 

Instructions to stream the Update Series in other Podcast apps
 

Access the Audio Lessons are also available in the AUAUniversity app and within the AUAU  lesson Content page.

Download on the App StoreGet it on Google Play

 

 

Target Audience

  • Urologist
  • Resident

Learning Objectives

At the conclusion of this continuing medical education activity, the participant will be able to define the role of fluoroquinolones in treating urinary tract infections, describe the adverse side effects and complications associated with fluoroquinolones, and manage urinary tract infections employing fluoroquinolones and alternatives.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Course opens: 
08/01/2022
Course expires: 
08/31/2025
List Price:
$99.00
Rating: 
0

Education Council Disclosures

PDF iconEducation Council Disclosures_2022.pdf

COI Review Work Group Disclosures

PDF iconCOI Review Work Group_2022.pdf

Update Series Editorial Committee Disclosures

PDF iconUpdate Series Editorial Committee_2022.pdf

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

Author(s)

Curtis Nickel, MD

has a financial relationship (Consultant or Advisor (General Urology)) with HengRui;.
has a financial relationship (Consultant or Advisor (General Urology)) with TEVA;.
has a financial relationship (Meeting Participant or Lecturer (General Urology)) with UTIVA;.
has a financial relationship (Scientific Study or Trial (General Urology)) with MicroGenDx;.
has a financial relationship (Consultant or Advisor (General Urology)) with Seikagaku Corporation;.
has a financial relationship (Consultant or Advisor (General Urology)) with Farr Laboratories;.
has a financial relationship (Scientific Study or Trial (General Urology)) with Inmunotek;.
has a financial relationship (Consultant or Advisor (General Urology)) with Alivio Therapeutics;.
has a financial relationship (Consultant or Advisor (General Urology)) with Valensa;.
has a financial relationship (Scientific Study or Trial (General Urology)) with RedLeaf Medical;.
has a financial relationship (Consultant or Advisor (General Urology)) with OM Pharma;.

Florian Wagenlehner

has a financial relationship (Consultant or Advisor (General Urology)) with OM-Pharma;.
has a financial relationship (Consultant or Advisor (General Urology)) with Spero;.
has a financial relationship (Consultant or Advisor (General Urology)) with GSK;.
has a financial relationship (Consultant or Advisor (General Urology)) with Rempex;.
has a financial relationship (Consultant or Advisor (General Urology)) with Bionorica;.
has a financial relationship (Consultant or Advisor (General Urology)) with MSD;.
has a financial relationship (Scientific Study or Trial (General Urology)) with European Association of Urology;.
has a financial relationship (Consultant or Advisor (Oncology)) with AstraZeneca;.
has a financial relationship (Consultant or Advisor (General Urology)) with Sysmex;.
has a financial relationship (Consultant or Advisor (General Urology)) with Rosen Pharma;.
has a financial relationship (Consultant or Advisor (General Urology)) with Sysmex;.
has a financial relationship (Consultant or Advisor (General Urology)) with Janssen;.
has a financial relationship (Consultant or Advisor (General Urology)) with Rosen Pharma;.
has a financial relationship (Consultant or Advisor (General Urology)) with Calixa;.
has a financial relationship (Consultant or Advisor (General Urology)) with OM-Pharma;.
has a financial relationship (Scientific Study or Trial (General Urology)) with Achaogen;.
has a financial relationship (Consultant or Advisor (General Urology)) with GSK;.
has a financial relationship (Consultant or Advisor (General Urology)) with Bionorica;.
has a financial relationship (Consultant or Advisor (General Urology)) with Vifor Pharma;.
has a financial relationship (Scientific Study or Trial (General Urology)) with SelectImmune Pharma AB;.
has a financial relationship (Meeting Participant or Lecturer (General Urology)) with Pfizer;.
has a financial relationship (Consultant or Advisor (General Urology)) with Klosterfrau;.
has a financial relationship (Scientific Study or Trial (General Urology)) with SelectImmune Pharma AB;.
has a financial relationship (Consultant or Advisor (General Urology)) with Cerexa;.
has a financial relationship (Meeting Participant or Lecturer (General Urology)) with Pfizer;.
has a financial relationship (Consultant or Advisor (Oncology)) with Astellas;.
has a financial relationship (Consultant or Advisor (General Urology)) with Janssen;.
has a financial relationship (Consultant or Advisor (General Urology)) with Calixa;.
has a financial relationship (Scientific Study or Trial (General Urology)) with Achaogen;.
has a financial relationship (Consultant or Advisor (General Urology)) with Shionogi;.
has a financial relationship (Consultant or Advisor (General Urology)) with Qiagen;.
has a financial relationship (Consultant or Advisor (General Urology)) with Vifor Pharma;.
has a financial relationship (Consultant or Advisor (General Urology)) with MSD;.
has a financial relationship (Consultant or Advisor (General Urology)) with Shionogi;.
has a financial relationship (Scientific Study or Trial (General Urology)) with European Association of Urology;.
has a financial relationship (Consultant or Advisor (General Urology)) with Qiagen;.
has a financial relationship (Consultant or Advisor (Oncology)) with AstraZeneca;.
has a financial relationship (Consultant or Advisor (General Urology)) with Klosterfrau;.
has a financial relationship (Consultant or Advisor (General Urology)) with Cerexa;.
has a financial relationship (Consultant or Advisor (Oncology)) with Astellas;.
has a financial relationship (Consultant or Advisor (General Urology)) with Spero;.
has a financial relationship (Consultant or Advisor (General Urology)) with Rempex;.

CME CREDITS EXPIRATION:

Please note: CME Credits expire after three years of original release date. Answers must be submitted by the CME credits expiration deadline to receive credit for that year. Refer to CME expiration table below:

 

CME Credits Expiration Date                             

2022 Update Series                                       

Month, 2025

2021 Update Series

Month, 2024

2020 Update Series

Month, 2023

2019 Update Series

Month, 2022

2018 and prior

Not eligible for CME credits.

This self-study continuing medical education activity is designed to provide urologists, Board candidates and/or residents affordable and convenient access to the most recent developments and techniques in urology.

METHOD OF PARTICIPATION:

Participants receive 5 lessons per month for 8 months for a total of 40 lessons. Each lesson is designated for a maximum of 1.0 AMA PRA Category 1 Credit™. To earn credit, participants must read the educational material provided for each lesson, pass its corresponding online posttest with at least 80% accuracy, submit the online evaluation and claim CME.

ACCREDITATION:

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION:

The American Urological Association designates this enduring activity for a maximum of 40 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS:

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT:

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

REPRODUCTION PERMISSION:

Reproduction of written materials developed for this AUA activity is prohibited without the written permission from individual authors and the American Urological Association.

PEER REVIEW:

Peer review is the principle mechanism by which the quality of the AUA Update Series content is judged by the AUA Update Series Editorial Committee.

Released date: August, 2022
Expiration date: August, 2025

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation

Price

List Price:
$99.00
Please login or register to take this course.